Shuttle Pharmaceuticals Holdings Inc (OQ:SHPH)
Business Focus: Pharmaceuticals
Apr 03, 2024 09:00 am ET
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief...
Apr 03, 2024 07:00 am ET
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with...
Mar 22, 2024 09:00 am ET
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
GAITHERSBURG, Md., March 21, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023.
Mar 05, 2024 09:00 am ET
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief...
Mar 05, 2024 07:00 am ET
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong...
Feb 13, 2024 07:00 am ET
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
ROCKVILLE, Md., Feb. 13, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("SHPH" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), along with its wholly-owned subsidiary, Shuttle Diagnostics, Inc., a Maryland corporation ("Diagnostics"), today announced its intent to commence a Rights Offering where it plans to raise up to $4.5 million through the distribution of subscription rights and the exercise thereof, which full rights will entitle ex
Jan 23, 2024 03:30 pm ET
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
ROCKVILLE, Md., Jan. 23, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1, 2024.
Jan 08, 2024 08:00 am ET
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
ROCKVILLE, Md., Jan. 8, 2024 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence the Phase II study.
Dec 11, 2023 08:00 am ET
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the next phase of development of Ropidoxuridine. Ropidoxuridine is Shuttle Pharma's lead radiation sensitizer candidate for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.
Dec 06, 2023 07:00 am ET
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 65th Emerging Growth Conference on December 6th and 7th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors,...
Nov 30, 2023 08:00 am ET
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 10:15am ET
Nov 14, 2023 08:00 am ET
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
ROCKVILLE, Md., Nov. 14, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
Oct 31, 2023 09:00 am ET
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
ROCKVILLE, Md., Oct. 31, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered into an exclusive agreement to license certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's predictive biomarker program for prostate cancer.
Oct 10, 2023 09:00 am ET
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
ROCKVILLE, Md., Oct. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.
Sep 25, 2023 09:00 am ET
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Company remains on track to initiate the clinical trial in Q4 of 2023
Sep 13, 2023 09:00 am ET
Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair
ROCKVILLE, Md., Sept. 13, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced its commitment to improving outcomes for patients with prostate cancer through its participation in the Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair. The event, held on September 16, 2023 at Hampton University, is offering free early detection exams for prostate cancer. Dr. Tyvin Ri
Sep 11, 2023 09:00 am ET
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
ROCKVILLE, Md., Sept. 11, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled "Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof."
May 26, 2023 09:00 am ET
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
ROCKVILLE, Md., May 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
May 17, 2023 09:00 am ET
Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
ROCKVILLE, Md., May 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) (the "Company," or "Shuttle Pharmaceuticals"), announced today that its Chief Executive Officer, Anatoly Dritschilo, M.D., will be participating in a Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference (the "Conference") on Thursday, May 18, 2023. Management will also be conducting one-on-one meetings with inv
Mar 22, 2023 09:00 am ET
Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates
ROCKVILLE, Md., March 22, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model. The pre-clinical work outlined in the research agreement with George
Mar 15, 2023 09:00 am ET
Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
ROCKVILLE, Md., March 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022.
Mar 09, 2023 08:00 am ET
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
ROCKVILLE, Md., March 9, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has signed an agreement with the University of Iowa (UI) Pharmaceuticals for formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. This is expected to be the final step required in the drug manufacturing process for use in Shuttle Pharma's upcoming Phase II clinical trial evaluating
Jan 26, 2023 03:15 pm ET
Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31
ROCKVILLE, Md., Jan. 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced Anatoly Dritschilo, M.D., CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
Jan 17, 2023 08:00 am ET
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
ROCKVILLE, Md., Jan. 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Chairman and Chief Executive Officer, Anatoly Dritschilo, M.D., CEO, and other Shuttle Pharmaceuticals team members will ring the Nasdaq opening bell on Wednesday, January 18, 2023.
Jan 12, 2023 03:15 pm ET
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
ROCKVILLE, Md., Jan. 12, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor. Shuttle Pharmaceuticals will receive initial gross proceeds of $4.0 million. In addition, the four-year warrant to purchase up to approximately 1.018 million shares of Shuttle Pharmaceuticals' comm
Jan 10, 2023 08:00 am ET
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md., Jan. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript discussing immune responses taking place in patients after radiation therapy for cancer. The manuscript, titled, "Radiation therapy induces innate immune responses in patients treated for prostate cancers," by Dr. Amrita K Cheema, was published in Clinical Cancer Research, a journal affiliat
Dec 06, 2022 08:00 am ET
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md., Dec. 6, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript discussing prostate cancer cell lines derived from African American men for precision medicine. The manuscript, titled "Novel paired normal prostate and prostate cancer model cell systems derived from African American patients," by Dr. Mira Jung was published in Cancer Research Communications
Nov 15, 2022 08:00 am ET
Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update
ROCKVILLE, Md., Nov. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.
Nov 03, 2022 09:00 am ET
Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, today announced it has engaged Theradex Oncology, a leading clinical research organization ("CRO"), to help prepare for its upcoming clinical study of Ropidoxuridine.
Nov 01, 2022 09:00 am ET
Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors
ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director. Dr. Jacobs will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
Sep 20, 2022 09:00 am ET
Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
Agreement to help advance lead clinical sensitizer drug candidate
Sep 15, 2022 08:30 am ET
Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment
Company awarded patents in the U.S. and Hong Kong
Sep 06, 2022 09:00 am ET
Shuttle Pharmaceuticals Announces Closing of Initial Public Offering
ROCKVILLE, Md., Sept. 6, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, today announced the closing of its initial public offering (IPO) of 1,225,888 units of common stock and warrants at a public offering price of $8.125 per unit, for aggregate proceeds of $9,960,340, before deducting underwriting discounts and estimated offering expenses. Each unit consisted of one share of commo
Aug 31, 2022 01:20 pm ET
Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"
Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effects
Aug 30, 2022 04:40 pm ET
Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering
ROCKVILLE, Md., Aug. 30, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, announced today the pricing of its initial public offering of 1,225,888 units of common stock and warrants, which priced at $8.125 per unit, raising gross proceeds of $9,960,340. Each unit consists of one share of common stock and a warrant to purchase one share of common stock. Each of the warrants is immediat
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
